Table 1 The demographic and clinical data of 90 RRMS patients
Mean ± SD (range) | |
|---|---|
Age (years) | 32.74 ± 8.43(16–55) |
Sex (male/female) (%) | (24/66) (26.76%/73.3%) |
Education years | 11.80 ± 4.84 (0–20) |
Disease duration (months) | 55.44 ± 50.15(3–240) |
Number of relapses | 3.41 ± 2.36 (2–12) |
Age at onset (years) | 27.14 ± 7.81(12–45) |
EDSS | 3.2 ± 1.73(1–5.5) |
DMT duration (months) | 19.83 ± 21.34(0–96) |
Time to start DMT (months) | 35.60 ± 44.71(3– 228) |
SDMT | 28.07 ± 11.78(6–54) |
CVLT | 42.32 ± 12.46(14–74) |
BVM-RT | 16.13 ± 8.17(0–32) |
Total WM-LL | 18.14 ± 15.88(0.07–62.40) |
Juxtacortical WM-LL | 5.69 ± 10.72 (0.02–58.43) |
Periventricular WM-LL | 11.66 ± 13.81 (0–48.81) |
Infratentorial WM-LL | 0.24 ± 0.45 (0–1.68) |
Cognitive impairment (yes/no) (%) | (29/61) (32.2%/67.8%) |
Current DMT | |
No treatment number (%) | 7 (7.8%) |
Interferon B number (%) | 50 (55.6%) |
Fingolimod number (%) | 26 (28.9%) |
Teriflunomide number (%) | 3 (3.3%) |
Rituximab number (%) | 2 (2.2%) |
Ocrelizumab number (%) | 2 (2.2%) |